SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2000 LabOne, Inc. ---------------------------------------------------- (Exact name of registrant as specified in its charter) Missouri 0-16946 43-1039532 -------------------- ----------- --------------- (State or other jurisdiction (Commission (I. R. S. Employer of incorporation) File Number) Identification No.) 10101 Renner Blvd., Lenexa, KS 66219 ---------------------------------------- ------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: 913-888-1770 ------------ Page 1 of 2 Item 5. Other Events LabOne, Inc. announced that Robert D. Thompson, executive vice president, chief operating officer and chief financial officer has resigned from the company effective January 24, 2000, to become CEO and president of Epitope, Inc., a medical device and diagnostic product company. Last year, LabOne tested more than 800,000 oral fluid specimens, and is Epitope's largest customer in the insurance testing market. In addition to insurance, LabOne is working with STC Technologies and Epitope on the commercial launch of the only laboratory oral fluid drugs of abuse product in the marketplace. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. LabOne, Inc. Date: January 10, 2000 By /s/ Kurt E. Gruenbacher ------------------------ Kurt E. Gruenbacher, V.P. Finance, CAO and Treasurer Date: January 10, 2000 By /s/ W. Thomas Grant ------------------------ W. Thomas Grant, Chairman, President and Chief Executive Officer Page 2